Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)

BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, reduced exacerbations and improved lung function in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation in the phase 3 BOREAS trial. OBJECTIVE: To assess clinical outcomes in patients from BOREAS by emphysema status. METHODS: Patients with COPD and type 2 inflammation (screening blood eosinophils

• Bhatt, S. P.
• Rabe, K. F.
• Hanania, N. A.
• Vogelmeier, C. F.
• Bafadhel, M.
• Christenson, S. A.
• Papi, A.
• Singh, D.
• Laws, E.
• Dakin, P.
• Maloney, J.
• Lu, X.
• Bauer, D.
• Bansal, A.
• Robinson, L. B.
• Abdulai, R. M.